The study is testing a new medicine for weight control in people with overweight or obesity. The aim of the study is to find out how safe the study medicine is and how it works in the body. Participants will either get NNC9204-1706 (the new study medicine) or placebo (a dummy medicine) - which treatment participants get is decided by chance. NNC9204-1706 is a new medicine which cannot be prescribed by doctors. Participants will get an injection under the skin of participants' stomach each morning for 10 weeks. A medical tool called NovoPen®4 will be used for the injection. Participants must change the part of the pen including the medicine (the cartridge) each day. The study will last for about 16 weeks. Participants will have at least 17 clinic visits and 10 phone calls with the study doctor. At certain times during the study, participants will have blood drawn and 3 different kinds of heart tests (electrocardiograms). Study doctor will ask participants to answer mental health surveys.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
60
Participants will receive NNC9204-1706 subcutaneous (s.c., under the skin) injection(s) once daily (OD) for 10 weeks. They will either receive the same dose throughout the trial, or the dose will be escalated over a period of 1-3 weeks and continued for at least 7 weeks at the same dose.
Participants will receive matching placebo (NNC9204-1706) s.c., injection(s) OD for 10 weeks.
Novo Nordisk Investigational Site
Overland Park, Kansas, United States
Number of treatment emergent adverse events (TEAEs)
Count of adverse events.
Time frame: Days 1-84
Change in time-profile (msec) in individual corrected QT interval (ΔQTcI)
Measured in msec.
Time frame: Day 1, Day 84
AUC0-24h,SS (h*nmol/L); the area under the NNC9204-1706 plasma concentration-time curve from time 0 to 24 hours at steady state
Measured in h\*nmol/L.
Time frame: Days 1-84
Cmax,SS (nmol/L); the maximum plasma concentration of NNC9204-1706 at steady state
Measured in nmol/L.
Time frame: Days 1-84
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.